On October 27, 2021 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, reported that it will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021 (Press release, Sarepta Therapeutics, OCT 27, 2021, View Source [SID1234592054]). Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2021 financial results and to provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 7131019. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2021 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

On October 27, 2021 Biofrontera AG reported that its US-subsidiary Biofrontera Inc. intends to raise capital by means of an initial public offering and a stock exchange listing in the United States ("IPO") (Press release, Biofrontera, OCT 27, 2021, View Source [SID1234592075]). On October 1, 2021, Biofrontera AG announced that within the scope of the IPO, up to 3,450,000 shares of Biofrontera Inc. are to be placed with US-investors with a price range of USD 5.00 to USD 7.00 per share and that no existing shares of Biofrontera Inc. held by Biofrontera AG will be offered.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on consultation with the underwriters, Biofrontera Inc. now intends to modify these terms and conditions: Up to 3,565,000 units ("Units") consisting of one new Biofrontera Inc. share and one warrant entitling the holder to one additional new Biofrontera Inc. share shall be offered in the IPO. The price range for the Units offered in the IPO is USD 5.00 to USD 7.00 per Unit. The price of a Unit is allocated between the share and the warrant. Each warrant has an exercise price equal to the initial public offering price and expires five years from the date of issuance.

The Management Board has resolved, with the consent of the Supervisory Board, that it is in favor of the above adjustments to the terms and conditions of the IPO being made by Biofrontera Inc.

A registration statement relating to the securities to be offered in the IPO has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This offering is being made only by means of a prospectus which has been filed with the SEC as part of a registration statement once it is effective.

This public disclosure of inside information according to article 17 MAR shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On October 26, 2021 GlycoMira Therapeutics reported that it received a $2.8M award from the National Institutes of Health to develop its lead compound, GM-1111, as a therapeutic for oral mucositis arising from radiation treatment of head and neck cancers (Press release, GlycoMira Therapeutics, OCT 26, 2021, View Source [SID1234632164]). The award will enable the completion of the requisite pre-clinical studies necessary for filing an Investigational New Drug (IND) application to initiate human clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral mucositis is a common, debilitating complication characterized by painful, severe ulcerations of the mouth that develop in head and neck cancer patients receiving chemoradiation therapy. The disease substantially degrades quality of life and compromises treatment and prognosis. Over 67K new head and neck cancer cases occur annually in the U.S., and the global market for the treatment of such cancers is projected to reach $2.3B by 2025.

GlycoMira’s pivotal studies in pre-clinical models demonstrate a significant reduction in the occurrence and severity of oral mucositis. Significant reductions in tumor volume were additionally observed in head and neck squamous cell carcinoma models when GM-1111 was administered as an adjuvant to radiation therapy. GM-1111 is believed to suppress tumor growth by blocking innate immune receptors and angiogenic factor-mediated cell signaling, as well as inhibiting cancer stem cell growth which is expected to improve therapeutic outcomes.

Dr. Stephen Sonis, Professor of Oral Medicine at Harvard stated, "Oral mucositis remains a common and devastating side effect of radiation therapy for head and neck cancers. Critically, it is often a reason why patients are unable to complete optimal anti-cancer treatment. I am excited to collaborate with the GlycoMira team so that we can accelerate the move of their innovative technology into the clinic."

On October 26, 2021 EpiAxis Therapeutics reported that it is among 25 emerging companies that will be showcased at Wholesale Investor’s STEM 2021 Conference on Thursday, October 28 (Press release, EpiAxis Therapeutics, OCT 26, 2021, View Source;utm_medium=rss&utm_campaign=epiaxis-to-present-at-stem-2021-conference [SID1234591924]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Breakthroughs in Science, Technology, Engineering, and Mathematics (STEM) have formed the foundation for critical disruptions across many industries and sectors in the last decade. STEM is the realm where our most significant problems are discovered, and the mechanism whereby these problems can be solved.

EpiAxis recently joined Wholesale Investor, Australasia’s leading investment platform that connects innovative, emerging companies that are looking to raise capital with an active, engaged and growing ecosystem of more than 29,300 high-net-worth investors, fund managers, family offices, PE and VC firms, government bodies and industry participants.

CEO Jeremy Chrisp will present at the Virtual Investor Showcase to raise awareness and visibility for EpiAxis’ epigenetic pipeline of therapies, which work differently to existing – and often toxic – cancer treatments by uniquely reprograming (re-train) the cancer cells back towards normal cells. Chrisp will discuss how our epigenetic science aims to maintain and extend cancer remission, with low side effects.

The showcase includes everything investors need to capitalise on STEM investment opportunities:

25 emerging companies solving problems in the space of; Renewable Energy, Life Sciences, AgriTech, FinTech, Data, and AI
Panel sessions from globally leading STEM investors discussing their due diligence process and sectors of interest
Live Q&A/interaction with panellists
Ability to conduct one-on-one meetings with founders of ventures

On October 26, 2021 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that it will host a third quarter 2021 investor call on Tuesday, November 2, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update (Press release, Pieris Pharmaceuticals, OCT 26, 2021, View Source [SID1234591941]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed here.

For those unable to participate in the conference call or listen to the webcast, a replay will be available on the Investors section of the Company’s website, www.pieris.com.